If you need any assistance voting your shares, please contact our proxy solicitor at:
D.F. King & Co, Inc.
48 Wall Street, 22nd Floor
New York, NY 10005
Call Toll-Free:
(800) 347-4750
Banks and Brokers
Call: (212) 269-5550
BIOL@dfking.com
About BIOLASE
BIOLASE is a medical device company that
develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASEs products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASEs proprietary laser products
incorporate approximately 271 patented and 40 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASEs innovative products provide cutting-edge
technology at competitive prices to deliver superior results for dentists and patients. BIOLASEs principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical
applications. BIOLASE has sold over 41,200 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASEs core dental market and other adjacent medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase Express, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at
www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking
Statements
This communication contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve
significant risks and uncertainties, including statements, regarding the anticipated effects of stockholder approval of matters to be voted on at BIOLASEs 2021 annual meeting of stockholders (the Annual Meeting). Forward-looking
statements can be identified through the use of words such as may, might, will, intend, should, could, can, would, continue, expect,
believe, anticipate, estimate, predict, outlook, potential, plan, seek, and similar expressions and variations or the negatives of these terms or other
comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASEs current expectations and speak only as of the date of this communication. Actual results may differ
materially from BIOLASEs current expectations depending upon a number of factors. These factors include, among others, those risks and uncertainties that are described in the definitive proxy statement filed by BIOLASE with the Securities and
Exchange Commission (the SEC) in connection with the Annual Meeting and in the Risk Factors section of BIOLASEs most recent annual report on Form 10-K filed with the SEC.
Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.